The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond

Heart. 2022 May;108(10):800-806. doi: 10.1136/heartjnl-2021-320150.

Abstract

In this article, we provide a historical view of key aspects of British Cardiovascular Society (BCS) influence in clinical trials of ischaemic heart disease (IHD) followed by key research and developments, notable publications and future perspectives. We discuss the role of the BCS and its members. The scope of this article covers clinical trials in stable IHD and acute coronary syndromes, including interventions relating to diagnosis, treatment and management. We discuss the role of the BCS in supporting the original RITA trials. We highlight the changing face of angina and its management providing contemporary and future insights into microvascular disease, ischaemic symptoms with no obstructive coronary arteries and, relatedly, myocardial infarction with no obstructive coronary arteries. The article is presented as a brief overview of the BCS in IHD research, relationships with stakeholders, patient and public involvement and clinical trials from the perspective of past, present and future possibilities.

Keywords: Cardiac Rehabilitation; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Diagnostic Imaging.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angina, Stable*
  • Coronary Artery Disease*
  • Humans
  • Myocardial Ischemia* / diagnosis
  • Myocardial Ischemia* / therapy
  • Percutaneous Coronary Intervention*